MKMuhammed Doğukan Kalenderoğlu

Muhammed Doğukan Kalenderoğlu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Muhammed Doğukan Kalenderoğlu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Tiered Genetic Diagnostic Approach in Newborns With Major Congenital Anomalies: Experience From a Tertiary NICU

    by Hatice Mutlu, Ece Eker, Yasemin Ezgi Köstekci, Ferhan Demirtaş, Doğan Kaymaz, Muhammed Doğukan Kalenderoğlu, Arzu Ay, Şule Altıner, Emel Okulu, Ömer Erdeve, et al.

    Background: Major congenital anomalies (MCAs) are a leading cause of neonatal morbidity and mortality and frequently reflect underlying chromosomal, copy number, or single‐gene defects. In neonates with multiple MCAs, early molecular diagnosis is critical but remains challenging due to phenotypic heterogeneity, overlapping developmental pathways, and limitations in selecting the most appropriate genetic test. Methods: This prospective study included 146 neonates with congenital anomalies who were referred for genetic consultation from a tertiary neonatal intensive care unit between April 2022 and May 2025. A major congenital anomaly was defined as a structural abnormality present at birth with significant medical, functional, or cosmetic consequences, while multiple congenital anomalies were defined as two or more major anomalies involving different organ systems. Clinical features were systematically annotated using Human Phenotype Ontology terms and classified according to organ system and embryological origin. A tiered diagnostic strategy was applied, including conventional cytogenetic analysis, chromosomal microarray analysis (CMA), whole‐exome sequencing (WES), and rapid‐WES (rWES) in selected critically ill neonates. Results: Cardiovascular anomalies were the most frequent (45.9%), and 88 of 146 neonates (60.3%) had two or more MCAs. Cytogenetic testing identified numerical chromosomal abnormalities in eight neonates. CMA detected pathogenic or likely pathogenic copy number variants in 6 of 65 tested cases (9.1%). In CMA‐negative patients, WES achieved a diagnostic yield of 41.4%, identifying variants in genes involved in multisystem developmental pathways. Rapid WES established definitive molecular diagnoses in two of three critically ill neonates within 72 h, directly influencing clinical management. Embryological analysis revealed recurrent co‐occurrence patterns, particularly cardiovascular–craniofacial and cardiovascular–genitourinary associations. Conclusion: A structured, tiered genomic approach enhances diagnostic yield in neonates with congenital anomalies. Integration of cytogenetics, CMA, and CNV‐aware exome sequencing provides a pragmatic and clinically actionable framework for molecular diagnosis in NICU settings and supports developmentally informed interpretation of complex phenotypes.

  • Isolated and Syndromic Talipes Equinovarus in Children: Differences in Clinical Presentation and Quality of Life

    by Ulkar Huseyinova, Muhammed Doğukan Kalenderoğlu, Ece Eker, Göksel Vatansever, Hatice Mutlu

    Objective: Talipes equinovarus (TEV) is a congenital foot deformity that can present either in an isolated form or as part of a syndromic condition. In syndromic TEV, dysmorphic features, systemic anomalies, and developmental delay are more frequently observed. This study aims to evaluate the differences in clinical characteristics, dysmorphic findings, and quality of life between isolated and syndromic forms of TEV in children. Materials and Methods: Ninety TEV patients (37 syndromic, 53 isolated) diagnosed between 2010 and 2022 were included. Demographic and clinical data were retrospectively reviewed. Additional anomalies and dysmorphic features were prospectively assessed. Quality of life in children aged ≥2 years and their caregivers was evaluated using the Pediatric Quality of Life Inventory (PedsQL). Results: Consanguinity, low birth weight and developmental delay were significantly more frequent in the syndromic TEV group (P=.005, P=.014, P=.014), with central nervous system anomalies being the most common. The PedsQL scores were highest in controls, followed by isolated TEV, and lowest in syndromic TEV (P < .001, P < .001). Quality of life was negatively correlated with dysmorphic feature count (P < .001). Conclusion: Quality of life in children with syndromic TEV is significantly affected by physical and psychosocial factors. Syndromic TEV is associated with a more complex clinical course and lower quality of life compared to the isolated form. Early diagnosis, clinical genetic evaluation, multidisciplinary management, and psychosocial support may enhance treatment success and quality of life.

  • Open Access

    Therapeutic apheresis: is it safe in children with kidney disease?

    by Muhammed Doğukan Kalenderoğlu, Elif Çomak, Gülşah Kaya Aksoy, Uğur Bilge, Osman Alphan Küpesiz, Mustafa Koyun, Sema Akman

    Background: Therapeutic apheresis (TA) is already used to treat various diseases in the field of nephrology. The aim of this study was to evaluate the frequency and types of complications that occur during TA in children with kidney disease. Methods: Records of children (≤ 18 years) who underwent TA between 2007 and 2022 were retrospectively reviewed. Children with missing data and those with a diagnosis of nonnephrological disease were excluded. Results: A total of 1214 TA sessions, including 1147 therapeutic plasma exchange (TPE) sessions and 67 immunoadsorption (IA) sessions, were performed on the 108 patients enrolled in the study. Forty-seven percent of the patients were male, and the mean age was 12.22 ± 4.47 years. Posttransplant antibody-mediated rejection (64.8%) and hemolytic uremic syndrome (14.8%) were the most common diagnoses indicating TA. Overall, 17 different complications occurred in 58 sessions (4.8%), and 53 sessions (4.6%) were not completed because of these complications. The distribution of complications among the patients was as follows: 41.4% had technical complications, 25.9% had allergic complications, and 32.7% had others. The most common technical complication was insufficient flow (37.5%). The incidence of complications was greater in patients aged 3–6 years than in patients in the other age groups (p = 0.031). The primary disease, type of vascular access, and rate of fresh frozen plasma/albumin use were similar between patients with and without complications (p values of 0.359 and 0.125 and 0.118, respectively). Conclusions: Our study showed that complications occurred in only 4.8% of TA sessions. The most common complication was technical problems. Graphical

  • Open Access

    Therapeutic Apheresis: Is It Safe In Children With Kidney Disease?

    by Muhamed Doğukan Kalenderoğlu, Elif Çomak, Gülşah Kaya Aksoy, Uğur Bilge, Osman Alphan Küpesiz, Mustafa Koyun, Sema Akman

    Therapeutic apheresis (TA) is already used in the treatment of various diseases in the field of nephrology. The aim of this study was to evaluate the frequency and types of complications that occur during TA in children with kidney disease. Method Records of children (≤ 18 years) who underwent TA between 2007 and 2022 were retrospectively reviewed. Children with missing data and those with a diagnosis of non-nephrological disease were excluded. Results A total of 1214 TA sessions, including 1147 therapeutic plasma exchange (TPE) sessions and 67 immunoadsorption (IA) sessions, were performed on 108 patients enrolled in the study. 47.2% of the patients were male and the mean age was 14 (1-18) years. Post-transplant antibody-mediated rejection (64.8%) and haemolytic uremic syndrome (14.8%) were the most common diagnoses indicating TA. Overall, 17 different complications occurred in 58 sessions (4.8%) and 53 sessions (4.6%) were not completed because of these. Technical problems accounted for 41.4%, allergic reactions 25.9% and citrate poisoning 5.2% of complications; the most common technical complication was inadequate flow (15.5%). The incidence of complications was higher in patients aged 3-6 years compared to other age groups (p=0.031). The primary disease, type of vascular access, and the rate of fresh frozen plasma/albumin use were similar between patients with and without complications ( p value 0.359 and 0.125 and 0.118, respectively). Conclusion Our study showed that complications occurred in only 4.8% of TA sessions. The most common complication was technical problems.